AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 82 min read$HAE

Haemonetics advances 17% on CSL supply deal (HAE:NYSE)

Haemonetics (HAE) rose 17% to a 52-week high after announcing a plasma supply agreement with CSL. The stock closed at $119.47, up $17.76.

Original reporting
seekingalpha.com
Published Oct 8, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics advances 17% on CSL supply deal (HAE:NYSE) — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$HAEBullishLow
01

Why it matters

The newly announced non‑exclusive plasma supply agreement with CSL triggered a 17% intraday rally in Haemonetics shares, reflecting market optimism about added revenue streams.

02

Market read

Contract news sparked a sharp rally, highlighting the importance of supply agreements in the plasma market.

03

What to watch

Deal size and duration are undisclosed; execution risk and competition could affect long‑term benefit.

Relevance 8/10Novelty 8/10Timing: after market close

Background

Haemonetics is a medical‑technology company focused on blood management; CSL is a global biotech specializing in plasma products.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics disclosed a non‑exclusive plasma supply agreement with CSL, sending the stock up 17% to a 52‑week high.

Expected impact

likely pressure as the market prices in the supply deal, but limited upside after sharp move

Evidence & confidence

Deal adds revenue potential but price already jumped, so further gains may be constrained.

Market effects

Sector

Boosts plasma collection and blood‑management sector, may benefit related suppliers.

Regional

Positive sentiment in US healthcare equities following the contract news.

Global

Limited global impact; CSL is an Australian biotech but the deal influences worldwide plasma supply dynamics.

Counterpoint

What could challenge this read

The 17% rally may be overdone; further upside limited after the sharp move.

Key entities

  • company
    Haemonetics

    US‑listed medical‑technology firm (ticker HAE).

  • company
    CSL

    Global biotech and plasma products company.

Read at source← All news

StoryHaemonetics secures CSL Plasma rollout of NexSys PCS devices across U.S. centers by end‑2027

Also covered by

6 outlets

Related articles

OCT 9
$HAEHigh

Haemonetics (HAE) Jumped, What Is Behind The Move?

Haemonetics (HAE) stock surged 13% after CSL Plasma agreed to use its NexSys PCS devices. The company's 90-day return is 56.81%, and its 1-year total shareholder return is 138.23%. Analysts debate its valuation, with some seeing it as 7% overvalued at $119.47, while a DCF model suggests it's 33% undervalued.

finance.yahoo.com2 min
OCT 8
$HAEMed

Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123

Haemonetics (HAE) stock rose 17.46% after Citigroup upgraded it to Buy with a $123 price target, up from $92. The upgrade follows a new supply agreement with CSL, which Citi expects to boost earnings. HAE reported Q1 revenue of $339.4M, net income of $33.0M, and free cash flow of $44.4M. The stock trades at a P/E of 50 and price-to-sales of 3.5.

timothysykes.com7 min
OCT 8
$HAEMedAI 8/10

Haemonetics shares jump as CSL sets 2027 rollout of plasma devices

Haemonetics (HAE) shares rose 13% to $115.20 after CSL Limited (CSL) announced plans to roll out Haemonetics' plasma collection devices in US centers by 2027. The non-exclusive agreement allows CSL to use Haemonetics' devices and disposables, with full implementation details pending. Haemonetics' 2027 guidance remains unchanged, and updates on financial impact are expected in November 2026.

finance.yahoo.com1 min
OCT 8
$HAEHighAI 8/10

Haemonetics (HAE) Shares Skyrocket, What You Need To Know

Haemonetics (HAE) shares rose 12.4% after CSL Plasma announced plans to fully deploy NexSys PCS devices in U.S. centers by 2027. Haemonetics maintained its fiscal 2027 guidance. The company's stock has seen volatility, with a 22.1% gain 11 months ago on strong Q3 results. HAE is up 43.8% YTD, hitting a 52-week high of $114.99.

financialcontent.com2 min